Probatebeta
Target

AKT1

RAC-alpha serine/threonine-protein kinase

As of the edition of 20 October 2026, AKT1 (RAC-alpha serine/threonine-protein kinase, UniProt P31749) has 20 drugs tested at it and 18 companies on the list, 9 on route A and 1 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P31749
How well studied
Chemical tools exist; no approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
56
Disease areas
Cancer; Skin and connective tissue; Urinary and reproductive; Blood and lymph; Immune system; Pregnancy and women's health; Digestive system; Hormones
Registered trials of its drugs
252

Drugs at this target

StatusCount
Marketed1
Active5
Went quiet3
Stopped10
Status not established1
Total20
DrugStatusFurthest phaseUS protection
CapivasertibMarketedPhase 3Ends 2033
IpatasertibActivePhase 3none listed
MK-2206StoppedPhase 2none listed
PerifosineWent quietPhase 3none listed
AfuresertibActivePhase 3none listed
UprosertibStoppedPhase 2none listed
MiransertibActivePhase 2none listed
Triciribine phosphateStoppedPhase 2none listed
LY-2780301StoppedPhase 2none listed
SM-020Status not establishedPhase 2none listed
ArchexinStoppedPhase 2none listed
GSK-690693StoppedPhase 1none listed

12 of 20 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A9
Route B1
Engaged7
Undetermined1
Total on the list18
Three companies on route A or B, with the route only
CompanyRoute
AstraZenecaRoute B
NovartisRoute A
TaihoRoute A

The other 15 companies at AKT1

In the product

18 companies in all; 15 are not named here, and no score is.

See the 18 companies at AKT1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at AKT1

Other targets in cancer